Skip to main content
UniHealth

Doctor search

Ajai Chari, MD

Hematology/Oncology · Berkeley

NPI 1376560136

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
5
Since medical school
27 years
University of California, Geffen School of Medicine, 1999

Offices

5 locations · UCSF Medical Group Business Services · University of California San Francisco · Regents of the University of California

Looking this up.

Hospitals listed: Mount Sinai Hospital · UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chari’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Mount Sinai HospitalNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Mount Sinai Health System, which runs 5 hospitalsHome of Tisch Cancer Institute, a National Cancer Institute designated cancer centrePatients rate it 3 of 5 · 69% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.9 (11 to 15) · 878 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.473, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.513, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.9 (3 to 5.1) · 878 cases, Jan 2024 – Dec 2024
  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Mount Sinai Hospital

Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 1 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Mount Sinai Hospital
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.9 (11 to 15) · 878 casesWorseJan 2024 – Dec 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.473BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.513BetterOct 2024 – Sep 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits3.9 (3 to 5.1) · 878 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.56 (0.9 to 2.21) · 4,503 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.03 (0.88 to 1.18)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths172.14 (136.78 to 207.5) · 260 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.4 · 155 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.6 · 168 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.1 · 139 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.9 · 785 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths12.4 · 774 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.8 · 589 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.2 · 10,714 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.08 (0 to 0.24) · 19,045 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.36 (0.21 to 0.52) · 20,760 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.47 (3.23 to 5.72) · 7,869 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.36 (0.41 to 2.3) · 3,840 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.62 (0.77 to 2.47) · 7,428 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.64 (5.02 to 10.27) · 3,845 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.23 (2.36 to 6.09) · 4,008 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.19 (0 to 2.45) · 1,428 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.93 (0.63 to 1.23) · 15,577 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths2.7 · 621 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.718No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.654No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections1.779No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.813No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.2 · 385 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.9 · 1,625 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits1.7 · 236 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits21.5 · 883 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits37.6 · 760 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits19.6 · 1,228 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits4.2 · 669 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 184 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.2 · 371 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.3 (9.3 to 16.1) · 681 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.1) · 1,157 casesNo differentJan 2024 – Dec 2024

What patients said (799 patients answered, 16% of those asked)

Patient survey stars by topic at Mount Sinai Hospital
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information3
Overall hospital rating3
Quietness2
Recommend hospital3
Share of patients giving the best answer at Mount Sinai Hospital
Room was "always" clean66%
Nurses "always" communicated well76%
Doctors "always" communicated well80%
Staff "always" explained60%
Yes, staff "did" give patients this information85%
Yes, staff "did" give patients information about help after discharge81%
Doctors "always" explained things so they could understand75%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)69%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand72%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night44%
"YES", patients would definitely recommend the hospital69%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms89%
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$140,537

Medicare paid this office $140,537 for 138 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)108$30,460$121
New patient visit (60+ min)46$6,566$143
Return visit (30+ min)49$4,715$77
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's110$3,084$15
Biopsy and aspiration of bone marrow sample for diagnosis23$1,459$63
See all 6 services
Every Original Medicare service billed
Long return visit (40+ min)108$30,460$121
New patient visit (60+ min)46$6,566$143
Return visit (30+ min)49$4,715$77
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's110$3,084$15
Biopsy and aspiration of bone marrow sample for diagnosis23$1,459$63
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or21$837$28

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Biopsy and aspiration of bone marrow sample for diagnosis–––––23

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

138 Original Medicare patients in 2024. Average age 73 · Women 45% · Also on Medicaid 16% · Health risk score 2.75. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 69% · Chronic kidney disease 41% · Diabetes 22% · Heart failure 20% · Coronary heart disease 17% · Atrial fibrillation 17% · Depression 17% · Cancer 13% · COPD 9%.

The office billed $1,179,345, Medicare allowed $180,699 and paid $140,537; for 2,773 services of 28 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20241382,773732.75$1,179,345$140,537
2023152177743.33$178,216$15,707
2022222730732.97$307,369$71,413
2021203723722.90$290,970$73,398
2020198636733.37$240,954$50,880
2019215830713.64$279,749$81,239
20182161,107713.51$329,261$122,179
2017178948703.58$259,387$98,160
2016192888703.33$231,150$83,424
2015163618712.73$185,700$51,658
2014150531692.97$159,175$42,403
2013151639692.66$183,400$44,255

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Long return visit (40+ min)65$8,037$113
Return visit (30+ min)30$2,012$65
Return visit (30+ min)27$1,836$68
Long return visit (40+ min)13$1,356$97

2022: 10 services

Original Medicare services billed in 2022
Long return visit (40+ min)60$14,827$128
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$11,897$94
Return visit (30+ min)81$11,254$82
Long return visit (40+ min)54$10,745$119
Return visit (30+ min)72$9,598$85
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes21$2,494$64
New patient visit (60+ min)15$2,482$165
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,320$178
Short return visit (20+ min)21$1,400$56
Short return visit (20+ min)12$849$61

2021: 11 services

Original Medicare services billed in 2021
Long return visit (40+ min)63$14,706$140
Return visit (30+ min)78$11,731$93
Return visit (30+ min)74$10,552$88
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes29$10,450$96
Long return visit (40+ min)46$10,237$135
New patient visit (60+ min)21$3,512$167
Short return visit (20+ min)27$2,029$60
Telephone medical discussion with physician, 21-30 minutes26$1,881$70
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$1,803$67
Short return visit (20+ min)19$1,284$64
Telephone medical discussion with physician, 11-20 minutes13$718$55

2020: 12 services

Original Medicare services billed in 2020
Long return visit (40+ min)67$8,960$94
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes31$8,232$97
Long return visit (40+ min)40$6,449$106
Return visit (30+ min)57$5,766$74
Return visit (30+ min)65$5,159$59
Telephone medical discussion with physician, 21-30 minutes28$2,364$72
Telephone medical discussion with physician, 21-30 minutes28$2,211$71
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes18$2,081$67
Telephone medical discussion with physician, 11-20 minutes30$1,491$48
Telephone medical discussion with physician, 11-20 minutes13$772$48
Short return visit (20+ min)15$720$45
Short return visit (20+ min)13$580$41

2019: 7 services

Original Medicare services billed in 2019
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a41$25,088$157
Long return visit (40+ min)102$21,419$96
Return visit (30+ min)119$14,601$69
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$9,391$94
New patient visit (60+ min)25$3,515$141
Short return visit (20+ min)38$2,265$46
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes19$1,853$64

2018: 7 services

Original Medicare services billed in 2018
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a79$69,933$157
Long return visit (40+ min)85$17,630$94
Return visit (30+ min)99$12,970$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes33$10,480$93
New patient visit (60+ min)28$4,093$146
Short return visit (20+ min)51$2,958$40
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$1,945$65

2017: 9 services

Original Medicare services billed in 2017
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a59$47,040$157
Long return visit (40+ min)69$13,767$95
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes46$13,027$89
Return visit (30+ min)87$12,934$65
New patient visit (60+ min)19$2,873$151
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,343$180
Short return visit (20+ min)33$2,055$43
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$1,470$61
Short return visit14$318$23

2016: 10 services

Original Medicare services billed in 2016
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a37$29,635$157
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes44$14,519$92
Long return visit (40+ min)65$12,758$96
Return visit (30+ min)88$12,570$68
Biopsy of bone marrow44$3,174$68
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,513$180
New patient visit (60+ min)15$2,264$151
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$1,842$64
Short return visit (20+ min)34$1,798$44
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service44$368$8

2015: 9 services

Original Medicare services billed in 2015
Long return visit (40+ min)85$22,489$95
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$11,363$92
Return visit (30+ min)41$4,531$62
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$3,648$64
New patient visit (60+ min)23$3,454$150
Biopsy of bone marrow26$1,909$68
Hospital discharge day management, more than 30 minutes12$1,239$95
Short return visit (20+ min)11$535$45
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service26$220$8

2014: 9 services

Original Medicare services billed in 2014
Return visit (30+ min)68$11,734$66
Long return visit (40+ min)56$10,864$94
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$9,836$90
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,308$178
New patient visit (60+ min)16$2,240$140
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes18$1,867$60
Short return visit (20+ min)19$807$38
Biopsy of bone marrow13$804$62
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service13$93$7

2013: 8 services

Original Medicare services billed in 2013
Return visit (30+ min)90$14,983$62
Long return visit (40+ min)61$9,767$86
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$8,581$88
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes22$2,784$61
Biopsy of bone marrow32$2,083$63
New patient visit (60+ min)11$1,449$132
Short return visit (20+ min)16$805$42
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service31$230$7

Medicaid work

$6,830 in 2024

Medicaid paid $6,830 for 34 billed services this clinician did in 2024, up to 14 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)34$6,830
Medicaid work by year
202434114$6,830

Drugs they prescribed that Part D paid

$2,105,534

Pharmacies billed $2,105,534 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

135 generic and 101 brand-name prescriptions · $2,105,534 in drug cost · 17 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Revlimid75$1,380,130$18,402
Lenalidomide30$423,140$14,105
Acyclovir28$336$12

Year by year

Part D prescribing by year
202423656None43%$2,105,534
2023190650% (0)None$505,476
202251196NoneNone$269,265
2021783106NoneNone$2,028,158
20209221090% (0)33%$2,441,725
2019757116NoneNone$1,146,564
20188511120% (0)30%$1,526,724
201755585None36%$995,897
201640466NoneNone$469,251
2015210577% (14)19%$104,599
2014317704% (14)16%$58,339
2013290555% (13)13%$66,840

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Revlimid13$249,866$19,220
Acyclovir76$716$9
Valacyclovir16$643$40
Prednisone21$67$3

2022: 10 drugs

Part D drugs prescribed in 2022
Xarelto24$18,479$770
Entecavir36$14,436$401
Eliquis15$10,902$727
Acyclovir200$2,201$11
Valacyclovir35$1,497$43
Pantoprazole13$504$39
Dexamethasone16$279$17
Gabapentin21$247$12
Hydrocortisone14$187$13
Prednisone29$83$3

2021: 14 drugs

Part D drugs prescribed in 2021
Venclexta56$725,317$12,952
Ninlaro52$593,391$11,411
Mozobil12$328,086$27,340
Zarxio24$67,516$2,813
Entecavir43$20,981$488
Xarelto18$14,458$803
Eliquis11$5,569$506
Acyclovir229$2,773$12
Valacyclovir35$1,631$47
Dexamethasone76$912$12
Hydrocortisone22$430$20
Gabapentin20$133$7
Amlodipine Besylate11$67$6
Prednisone27$59$2

2020: 17 drugs

Part D drugs prescribed in 2020
Ninlaro101$1,086,615$10,759
Venclexta49$608,610$12,421
Farydak12$132,336$11,028
Zarxio16$58,454$3,653
Entecavir64$29,169$456
Xarelto31$20,393$658
Eliquis18$8,874$493
Acyclovir216$2,403$11
Dexamethasone100$1,465$15
Doxycycline Hyclate11$1,235$112
Valacyclovir31$1,067$34
Hydrocortisone38$472$12
Ondansetron Odt28$346$12
Prednisone37$167$5
Tamsulosin16$144$9
Pantoprazole21$112$5
Gabapentin13$103$8

2019: 15 drugs

Part D drugs prescribed in 2019
Ninlaro43$426,313$9,914
Farydak11$99,287$9,026
Xarelto27$13,596$504
Entecavir24$11,359$473
Eliquis14$7,056$504
Levocarnitine20$4,610$231
Acyclovir191$1,528$8
Dexamethasone78$1,220$16
Doxycycline Hyclate14$1,192$85
Valacyclovir31$934$30
Hydrocortisone36$538$15
Amlodipine Besylate18$156$9
Gabapentin17$112$7
Pantoprazole20$105$5
Prednisone15$74$5

2018: 15 drugs

Part D drugs prescribed in 2018
Ninlaro93$907,852$9,762
Neupogen14$69,610$4,972
Enoxaparin25$17,250$690
Xarelto26$14,548$560
Doxycycline Hyclate27$3,435$127
Levocarnitine13$2,082$160
Acyclovir169$1,542$9
Dexamethasone75$1,039$14
Valacyclovir17$849$50
Hydrocortisone22$276$13
Levothyroxine18$233$13
Amlodipine Besylate28$138$5
Prednisone42$128$3
Allopurinol14$111$8
Gabapentin15$102$7

2017: 11 drugs

Part D drugs prescribed in 2017
Ninlaro48$450,847$9,393
Venclexta17$168,716$9,924
Xarelto24$9,704$404
Levocarnitine15$1,496$100
Doxycycline Hyclate14$875$63
Acyclovir76$542$7
Hydrocortisone25$498$20
Dexamethasone57$383$7
Pantoprazole20$160$8
Prednisone36$107$3
Amlodipine Besylate20$61$3

2016: 8 drugs

Part D drugs prescribed in 2016
Ninlaro27$240,133$8,894
Acyclovir48$354$7
Dexamethasone29$299$10
Atorvastatin22$235$11
Metoprolol15$215$14
Prednisone19$93$5
Pantoprazole13$68$5
Amlodipine Besylate19$61$3

2015: 3 drugs

Part D drugs prescribed in 2015
Dexamethasone16$389$24
Acyclovir33$287$9
Prednisone11$87$8

2014: 5 drugs

Part D drugs prescribed in 2014
Acyclovir52$490$9
Dexamethasone14$179$13
Warfarin17$155$9
Chlorhexidine Gluconate24$140$6
Prednisone20$86$4

2013: 4 drugs

Part D drugs prescribed in 2013
Acyclovir68$734$11
Dapsone22$702$32
Dexamethasone26$255$10
Chlorhexidine Gluconate11$67$6

Money from drug and device companies

$88,908 in 2025

Industry payments by year
20251475$76,559$88,908
20241794$75,119$96,599
20231744$48,192$51,276
20221228$35,710$37,247
20211120$30,047$30,261
20201037$57,039$64,232
2019990$54,162$86,988

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Takeda Pharmaceuticals U.S.A.Hyqvia$22,079
4 payments
  • Paid to speak or teach for Hyqvia · 2025-07-21 · $11,600
  • Travel for Hyqvia · 2025-07-21 · $124
  • Travel for Hyqvia · 2025-06-13 · $841
  • Travel for Hyqvia · 2025-06-06 · $9,515
Janssen Global ServicesDarzalex$15,854
24 payments
  • Consulting for Darzalex · 2025-12-19 · $1,125
  • Meals for Darzalex · 2025-12-05 · $39
  • Meals for Darzalex · 2025-12-05 · $17
  • Consulting for Darzalex · 2025-10-17 · $1,125
  • Consulting for Darzalex · 2025-10-03 · $3,750
  • Meals for Darzalex · 2025-09-15 · $12
  • Travel for Darzalex · 2025-09-15 · $10
  • Travel for Darzalex · 2025-09-15 · $9
  • Meals for Darzalex · 2025-09-15 · $59
  • Travel for Darzalex · 2025-09-14 · $275
  • Consulting · 2025-07-07 · $705
  • Travel for Darzalex · 2025-07-03 · $240
  • Consulting for Darzalex · 2025-07-03 · $1,125
  • Consulting for Darzalex · 2025-07-03 · $1,125
  • Consulting for Darzalex · 2025-06-27 · $1,500
  • Meals for Darzalex · 2025-06-26 · $20
  • Meals for Darzalex · 2025-06-14 · $21
  • Meals for Darzalex · 2025-06-14 · $14
  • Travel for Darzalex · 2025-06-12 · $65
  • Travel for Darzalex · 2025-06-12 · $30
  • Consulting for Darzalex · 2025-06-12 · $1,410
  • Meals for Darzalex · 2025-06-12 · $29
  • Consulting for Darzalex · 2025-01-31 · $525
  • Consulting for Darzalex · 2025-01-10 · $2,625
AstraZeneca Pharmaceuticals LPNone$9,208
5 payments
  • Travel · 2025-03-26 · $107
  • Consulting · 2025-02-20 · $6,560
  • Meals · 2025-02-14 · $35
  • Meals · 2025-02-14 · $45
  • Consulting · 2025-01-02 · $2,460
Grifols Shared Services North AmericaNone$8,250
1 payment
  • Consulting · 2025-12-04 · $8,250
GlaxoSmithKlineNone$8,093
5 payments
  • Consulting · 2025-06-25 · $2,800
  • Meals · 2025-06-11 · $23
  • Meals · 2025-06-11 · $70
  • Consulting · 2025-02-25 · $4,000
  • Consulting · 2025-01-30 · $1,200
AbbvieNone$5,075
1 payment
  • Consulting · 2025-10-17 · $5,075
See all 61 published payments
Every published payment
Janssen Global ServicesConsulting · 2025-12-19Darzalex$1,125
Janssen Global ServicesMeals · 2025-12-05Darzalex$39
Janssen Global ServicesMeals · 2025-12-05Darzalex$17
Grifols Shared Services North AmericaConsulting · 2025-12-04None$8,250
Legend Biotech USAConsulting · 2025-11-24Carvykti$2,513
Janssen BiotechMeals · 2025-11-18None$30
Janssen BiotechMeals · 2025-11-18None$40
Janssen BiotechMeals · 2025-11-17None$121
GenentechConsulting · 2025-11-06Venclexta$760
Janssen BiotechMeals · 2025-10-22Darzalex$75
Janssen Global ServicesConsulting · 2025-10-17Darzalex$1,125
AbbvieConsulting · 2025-10-17None$5,075
Janssen Global ServicesConsulting · 2025-10-03Darzalex$3,750
Janssen Scientific AffairsConsulting · 2025-09-18Darzalex$1,725
Janssen Global ServicesMeals · 2025-09-15Darzalex$12
Janssen Global ServicesTravel · 2025-09-15Darzalex$10
Janssen Global ServicesTravel · 2025-09-15Darzalex$9
Janssen Global ServicesMeals · 2025-09-15Darzalex$59
Janssen Global ServicesTravel · 2025-09-14Darzalex$275
Takeda Pharmaceuticals U.S.A.Paid to speak or teach · 2025-07-21Hyqvia$11,600
Takeda Pharmaceuticals U.S.A.Travel · 2025-07-21Hyqvia$124
Janssen Global ServicesConsulting · 2025-07-07None$705
Janssen Global ServicesTravel · 2025-07-03Darzalex$240
Janssen Global ServicesConsulting · 2025-07-03Darzalex$1,125
Janssen Global ServicesConsulting · 2025-07-03Darzalex$1,125
Janssen Global ServicesConsulting · 2025-06-27Darzalex$1,500
Janssen Global ServicesMeals · 2025-06-26Darzalex$20
GlaxoSmithKlineConsulting · 2025-06-25None$2,800
Kite PharmaConsulting · 2025-06-17Tecartus$1,800
Janssen Global ServicesMeals · 2025-06-14Darzalex$21
Janssen Global ServicesMeals · 2025-06-14Darzalex$14
Takeda Pharmaceuticals U.S.A.Travel · 2025-06-13Hyqvia$841
Janssen Global ServicesTravel · 2025-06-12Darzalex$65
Janssen Global ServicesTravel · 2025-06-12Darzalex$30
Janssen Global ServicesConsulting · 2025-06-12Darzalex$1,410
Janssen Global ServicesMeals · 2025-06-12Darzalex$29
GlaxoSmithKlineMeals · 2025-06-11None$23
GlaxoSmithKlineMeals · 2025-06-11None$70
Legend Biotech USATravel · 2025-06-09None$7
Legend Biotech USAMeals · 2025-06-09None$7
Takeda Pharmaceuticals U.S.A.Travel · 2025-06-06Hyqvia$9,515
Legend Biotech USAConsulting · 2025-05-07Carvykti$2,010
Janssen BiotechConsulting · 2025-05-05Talvey$2,820
GenentechConsulting · 2025-04-24Venclexta$380
Kite PharmaConsulting · 2025-04-24None$2,910
GenentechConsulting · 2025-04-03Venclexta$760
Kite PharmaMeals · 2025-03-27None$125
AstraZeneca Pharmaceuticals LPTravel · 2025-03-26None$107
Sekisui DiagnosticsGift · 2025-03-01None$300
GlaxoSmithKlineConsulting · 2025-02-25None$4,000
PfizerMeals · 2025-02-21Elrexfio$47
AstraZeneca Pharmaceuticals LPConsulting · 2025-02-20None$6,560
AstraZeneca Pharmaceuticals LPMeals · 2025-02-14None$35
AstraZeneca Pharmaceuticals LPMeals · 2025-02-14None$45
Regeneron Healthcare SolutionsConsulting · 2025-02-07None$2,781
GenentechConsulting · 2025-02-06Venclexta$380
Janssen Global ServicesConsulting · 2025-01-31Darzalex$525
GlaxoSmithKlineConsulting · 2025-01-30None$1,200
Janssen Global ServicesConsulting · 2025-01-10Darzalex$2,625
GenentechConsulting · 2025-01-08Venclexta$760
AstraZeneca Pharmaceuticals LPConsulting · 2025-01-02None$2,460
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $96,599

Payments by company in 2024
Takeda Pharmaceuticals U.S.A.None$33,544
6 payments
  • Meals · 2024-11-12 · $47
  • Travel · 2024-11-12 · $123
  • Travel · 2024-11-12 · $35
  • Consulting · 2024-11-12 · $20,451
  • Travel · 2024-07-18 · $7,023
  • Consulting · 2024-05-07 · $5,864
Octapharma USAIvig$13,231
18 payments
  • Honoraria for Ivig · 2024-06-14 · $2,500
  • Travel for Ivig · 2024-06-14 · $7,000
  • Travel for Ivig · 2024-06-14 · $241
  • Travel for Ivig · 2024-06-14 · $241
  • Travel for Ivig · 2024-06-14 · $241
  • Travel for Ivig · 2024-06-14 · $241
  • Travel for Ivig · 2024-06-14 · $29
  • Travel for Ivig · 2024-06-14 · $24
  • Travel for Ivig · 2024-06-14 · $13
  • Travel for Ivig · 2024-06-14 · $16
  • Travel for Ivig · 2024-06-14 · $59
  • Honoraria for Ivig · 2024-06-13 · $2,500
  • Travel for Ivig · 2024-06-13 · $60
  • Travel for Ivig · 2024-06-13 · $15
  • Travel for Ivig · 2024-06-13 · $17
  • Travel for Ivig · 2024-06-13 · $9
  • Travel for Ivig · 2024-06-13 · $11
  • Travel for Ivig · 2024-06-13 · $16
GenzymeSarclisa$10,891
6 payments
  • Meals for Sarclisa · 2024-09-13 · $21
  • Travel for Sarclisa · 2024-09-13 · $148
  • Meals for Sarclisa · 2024-07-11 · $167
  • Travel for Sarclisa · 2024-07-11 · $270
  • Travel for Sarclisa · 2024-07-11 · $312
  • Consulting for Sarclisa · 2024-07-11 · $9,972
E.R. Squibb & Sons L.L.C.None$9,347
6 payments
  • Consulting · 2024-12-23 · $3,343
  • Meals · 2024-12-06 · $15
  • Meals · 2024-06-10 · $950
  • Travel · 2024-06-10 · $1,005
  • Consulting · 2024-05-01 · $1,612
  • Consulting · 2024-04-04 · $2,422
GlaxoSmithKlineNone$7,315
7 payments
  • Meals · 2024-12-05 · $38
  • Meals · 2024-12-05 · $48
  • Meals · 2024-12-05 · $56
  • Consulting · 2024-10-08 · $4,800
  • Consulting · 2024-07-15 · $2,275
  • Meals · 2024-05-22 · $72
  • Meals · 2024-05-22 · $26
F. Hoffmann-La Roche AGNone$6,080
2 payments
  • Consulting · 2024-04-01 · $1,520
  • Consulting · 2024-01-29 · $4,560
Kite PharmaNone$4,120
3 payments
  • Consulting · 2024-04-12 · $4,020
  • Meals · 2024-03-22 · $50
  • Meals · 2024-03-22 · $50
AstraZeneca Pharmaceuticals LPNone$3,768
1 payment
  • Consulting · 2024-01-25 · $3,768
Legend Biotech USACarvykti$2,573
5 payments
  • Meals · 2024-12-05 · $74
  • Consulting for Carvykti · 2024-07-03 · $2,463
  • Travel · 2024-06-10 · $5
  • Travel · 2024-06-10 · $26
  • Meals · 2024-06-10 · $7
Karyopharm TherapeuticsXpovio$2,296
3 payments
  • Travel for Xpovio · 2024-09-25 · $16
  • Meals for Xpovio · 2024-09-25 · $243
  • Consulting for Xpovio · 2024-09-25 · $2,038
CelgeneNone$1,162
7 payments
  • Meals · 2024-12-10 · $27
  • Meals · 2024-12-10 · $27
  • Meals · 2024-12-10 · $59
  • Travel · 2024-04-12 · $470
  • Meals · 2024-04-12 · $500
  • Meals · 2024-02-29 · $49
  • Meals · 2024-02-29 · $29
Janssen Global ServicesDarzalex$724
3 payments
  • Meals for Darzalex · 2024-12-06 · $39
  • Meals for Darzalex · 2024-12-06 · $10
  • Consulting for Darzalex · 2024-06-14 · $675
Janssen Research & DevelopmentCarvykti$703
6 payments
  • Travel for Carvykti · 2024-11-21 · $68
  • Travel for Carvykti · 2024-11-21 · $517
  • Meals for Carvykti · 2024-11-21 · $18
  • Meals for Carvykti · 2024-11-21 · $14
  • Travel for Carvykti · 2024-11-21 · $41
  • Meals for Carvykti · 2024-11-21 · $45
AbbvieVenclexta$338
1 payment
  • Consulting for Venclexta · 2024-03-22 · $338
Sekisui DiagnosticsNone$250
1 payment
  • Gift · 2024-02-22 · $250
Janssen BiotechDarzalex$198
3 payments
  • Meals for Darzalex · 2024-12-07 · $67
  • Meals for Carvykti · 2024-12-07 · $67
  • Meals for Darzalex · 2024-09-25 · $63
AstraZeneca UKCalquence$60
1 payment
  • Meals for Calquence · 2024-12-06 · $60

2023: $51,276

Payments by company in 2023
GenzymeSarclisa$21,524
12 payments
  • Paid to speak or teach for Sarclisa · 2023-12-09 · $500
  • Meals for Sarclisa · 2023-12-08 · $70
  • Meals for Sarclisa · 2023-12-08 · $50
  • Consulting for Sarclisa · 2023-12-08 · $3,528
  • Paid to speak or teach for Sarclisa · 2023-11-02 · $250
  • Grant · 2023-06-06 · $84
  • Consulting for Sarclisa · 2023-06-01 · $7,840
  • Meals for Sarclisa · 2023-06-01 · $129
  • Meals for Sarclisa · 2023-06-01 · $48
  • Travel for Sarclisa · 2023-06-01 · $592
  • Travel for Sarclisa · 2023-06-01 · $592
  • Consulting for Sarclisa · 2023-06-01 · $7,840
CelgenePomalyst$6,457
6 payments
  • Consulting · 2023-11-27 · $1,038
  • Meals · 2023-06-08 · $14
  • Meals for Pomalyst · 2023-04-11 · $178
  • Consulting · 2023-03-06 · $2,422
  • Consulting · 2023-02-17 · $2,768
  • Consulting · 2023-02-17 · $37
E.R. Squibb & Sons L.L.C.None$4,881
3 payments
  • Consulting · 2023-02-17 · $2,768
  • Travel · 2023-02-17 · $37
  • Consulting · 2023-01-06 · $2,076
Kite PharmaTecartus$3,820
1 payment
  • Consulting for Tecartus · 2023-10-13 · $3,820
AmgenKyprolis$3,220
1 payment
  • Paid to speak or teach for Kyprolis · 2023-06-12 · $3,220
F. Hoffmann-La Roche AGNone$3,040
2 payments
  • Consulting · 2023-10-06 · $1,520
  • Consulting · 2023-10-01 · $1,520
GlaxoSmithKlineNone$2,689
3 payments
  • Meals · 2023-06-07 · $35
  • Meals · 2023-06-07 · $54
  • Consulting · 2023-04-20 · $2,600
Adaptive BiotechnologiesClonoseq$2,400
1 payment
  • Consulting for Clonoseq · 2023-05-10 · $2,400
AstraZeneca Pharmaceuticals LPNone$1,514
3 payments
  • Meals · 2023-12-12 · $75
  • Meals · 2023-12-12 · $69
  • Consulting · 2023-09-14 · $1,370
AbbVieVenclexta$803
2 payments
  • Meals for Venclexta · 2023-12-07 · $128
  • Consulting for Venclexta · 2023-06-30 · $675
Sekisui DiagnosticsNone$275
1 payment
  • Gift · 2023-01-01 · $275
Genentech USANone$163
1 payment
  • Meals · 2023-06-11 · $163
Karyopharm TherapeuticsXpovio$130
1 payment
  • Meals for Xpovio · 2023-11-30 · $130
Janssen Research & DevelopmentNone$130
1 payment
  • Meals · 2023-03-07 · $130
Janssen BiotechDarzalex$92
2 payments
  • Meals for Darzalex · 2023-06-02 · $32
  • Meals for Darzalex · 2023-03-24 · $60
Legend Biotech USANone$79
2 payments
  • Travel · 2023-06-08 · $47
  • Meals · 2023-06-08 · $32
Janssen Global ServicesCarvykti$59
2 payments
  • Meals for Carvykti · 2023-09-26 · $50
  • Meals for Carvykti · 2023-09-26 · $9

2022: $37,247

Payments by company in 2022
Takeda Pharmaceuticals U.S.A.Ninlaro$11,249
2 payments
  • Consulting · 2022-03-11 · $6,539
  • Consulting for Ninlaro · 2022-02-24 · $4,710
GlaxoSmithKlineNone$6,500
2 payments
  • Consulting · 2022-08-12 · $3,250
  • Consulting · 2022-01-18 · $3,250
Janssen BiotechTecvayli$4,834
6 payments
  • Meals for Tecvayli · 2022-12-09 · $61
  • Consulting for Tecvayli · 2022-07-28 · $2,057
  • Meals for Tecvayli · 2022-06-07 · $113
  • Consulting for Tecvayli · 2022-06-01 · $2,480
  • Meals for Darzalex · 2022-05-20 · $64
  • Meals for Darzalex · 2022-02-26 · $60
Karyopharm TherapeuticsXpovio$3,300
2 payments
  • Consulting for Xpovio · 2022-10-27 · $1,650
  • Consulting for Xpovio · 2022-10-04 · $1,650
GenzymeSarclisa$3,086
3 payments
  • Consulting for Sarclisa · 2022-08-01 · $749
  • Meals for Sarclisa · 2022-06-03 · $150
  • Consulting for Sarclisa · 2022-03-03 · $2,187
E.R. Squibb & Sons L.L.C.None$2,805
2 payments
  • Travel · 2022-09-13 · $37
  • Consulting · 2022-09-09 · $2,768
Adaptive BiotechnologiesClonoseq$2,400
1 payment
  • Consulting for Clonoseq · 2022-06-23 · $2,400
AmgenKyprolis$2,020
1 payment
  • Consulting for Kyprolis · 2022-04-07 · $2,020
AbbvieVenclexta$533
5 payments
  • Meals for Venclexta · 2022-11-04 · $5
  • Meals for Venclexta · 2022-11-04 · $68
  • Meals for Venclexta · 2022-11-04 · $45
  • Meals for Venclexta · 2022-11-04 · $6
  • Travel for Venclexta · 2022-11-03 · $409
Sekisui DiagnosticsNone$330
1 payment
  • Gift · 2022-01-01 · $330
CelgeneAbecma$125
1 payment
  • Meals for Abecma · 2022-12-09 · $125
Janssen Global ServicesCarvykti$65
2 payments
  • Meals for Carvykti · 2022-12-13 · $50
  • Meals for Carvykti · 2022-12-13 · $14

2021: $30,261

Payments by company in 2021
GlaxoSmithKlineNone$7,150
3 payments
  • Consulting · 2021-11-03 · $2,275
  • Consulting · 2021-07-23 · $2,925
  • Consulting · 2021-02-02 · $1,950
AbbVieNone$4,725
1 payment
  • Consulting · 2021-04-22 · $4,725
Karyopharm TherapeuticsXpovio$4,475
2 payments
  • Consulting for Xpovio · 2021-07-01 · $2,000
  • Paid to speak or teach for Xpovio · 2021-02-04 · $2,475
Takeda Pharmaceuticals U.S.A.Ninlaro$3,485
2 payments
  • Consulting for Ninlaro · 2021-03-09 · $2,904
  • Paid to speak or teach for Ninlaro · 2021-02-18 · $581
EpizymeTazverik$2,363
1 payment
  • Honoraria for Tazverik · 2021-04-29 · $2,363
PfizerNone$2,205
1 payment
  • Honoraria · 2021-09-09 · $2,205
Secura BioFarydak$1,900
2 payments
  • Consulting for Farydak · 2021-07-11 · $600
  • Consulting for Farydak · 2021-05-03 · $1,300
AmgenKyprolis$1,403
2 payments
  • Paid to speak or teach for Kyprolis · 2021-07-12 · $429
  • Consulting · 2021-05-28 · $974
Janssen BiotechDarzalex$1,338
3 payments
  • Meals for Darzalex · 2021-02-09 · $38
  • Meals for Darzalex · 2021-02-09 · $38
  • Consulting · 2021-01-08 · $1,263
GenzymeSarclisa$1,079
1 payment
  • Consulting for Sarclisa · 2021-01-04 · $1,079
CelgeneNone$138
2 payments
  • Meals · 2021-12-10 · $28
  • Meals · 2021-12-10 · $111

2020: $64,232

Payments by company in 2020
Takeda Pharmaceuticals U.S.A.None$13,777
6 payments
  • Consulting · 2020-01-24 · $9,999
  • Travel · 2020-01-24 · $242
  • Travel · 2020-01-24 · $3,094
  • Travel · 2020-01-24 · $164
  • Travel · 2020-01-24 · $57
  • Meals · 2020-01-24 · $222
GenzymeSarclisa$13,528
3 payments
  • Consulting for Sarclisa · 2020-07-13 · $7,767
  • Consulting for Sarclisa · 2020-06-08 · $2,517
  • Paid to speak or teach · 2020-03-06 · $3,244
AmgenKyprolis$10,196
7 payments
  • Paid to speak or teach for Kyprolis · 2020-10-12 · $3,124
  • Consulting for Kyprolis · 2020-06-19 · $275
  • Travel for Kyprolis · 2020-03-02 · $2,750
  • Consulting for Kyprolis · 2020-03-02 · $3,850
  • Travel for Kyprolis · 2020-02-28 · $127
  • Meals for Kyprolis · 2020-02-28 · $68
  • Meals for Kyprolis · 2020-02-06 · $3
CelgeneRevlimid$9,940
5 payments
  • Consulting for Pomalyst · 2020-12-22 · $2,250
  • Consulting for Revlimid · 2020-07-29 · $2,250
  • Consulting · 2020-06-19 · $2,250
  • Consulting for Revlimid · 2020-06-03 · $3,150
  • Meals · 2020-02-14 · $40
Karyopharm TherapeuticsXpovio$7,524
3 payments
  • Honoraria for Xpovio · 2020-12-21 · $2,184
  • Honoraria for Xpovio · 2020-07-13 · $3,300
  • Honoraria for Xpovio · 2020-06-11 · $2,040
Secura BioFarydak$3,811
7 payments
  • Travel for Farydak · 2020-02-28 · $80
  • Honoraria for Farydak · 2020-02-28 · $1,250
  • Paid to speak or teach for Farydak · 2020-02-15 · $123
  • Paid to speak or teach for Farydak · 2020-02-14 · $25
  • Honoraria for Farydak · 2020-02-14 · $2,000
  • Paid to speak or teach for Farydak · 2020-02-14 · $8
  • Paid to speak or teach for Farydak · 2020-01-29 · $325
Janssen BiotechDarzalex$2,309
3 payments
  • Consulting · 2020-08-14 · $1,263
  • Consulting for Darzalex · 2020-03-12 · $1,010
  • Meals for Imbruvica · 2020-01-09 · $36
Janssen Global ServicesDarzalex$1,515
1 payment
  • Consulting for Darzalex · 2020-11-12 · $1,515
GenentechVenclexta$1,320
1 payment
  • Consulting for Venclexta · 2020-10-30 · $1,320
E.R. Squibb & Sons L.L.C.Empliciti$311
1 payment
  • Travel for Empliciti · 2020-02-11 · $311

2019: $86,988

Payments by company in 2019
Takeda Pharmaceuticals U.S.A.Ninlaro$23,680
18 payments
  • Travel for Ninlaro · 2019-11-14 · $244
  • Travel for Ninlaro · 2019-11-14 · $664
  • Travel for Ninlaro · 2019-11-14 · $112
  • Travel for Ninlaro · 2019-11-14 · $526
  • Meals for Ninlaro · 2019-11-14 · $261
  • Travel for Ninlaro · 2019-07-12 · $343
  • Travel for Ninlaro · 2019-07-12 · $244
  • Meals for Ninlaro · 2019-07-12 · $85
  • Travel for Ninlaro · 2019-07-12 · $241
  • Meals for Ninlaro · 2019-07-12 · $182
  • Travel · 2019-01-18 · $8,809
  • Travel · 2019-01-18 · $705
  • Consulting · 2019-01-18 · $10,000
  • Travel · 2019-01-18 · $773
  • Meals · 2019-01-18 · $12
  • Travel · 2019-01-18 · $146
  • Consulting · 2019-01-18 · $30
  • Meals · 2019-01-18 · $304
AmgenKyprolis$20,975
25 payments
  • Travel · 2019-11-13 · $140
  • Meals · 2019-11-13 · $14
  • Meals for Kyprolis · 2019-10-05 · $94
  • Travel · 2019-08-21 · $289
  • Travel · 2019-08-06 · $410
  • Consulting for Kyprolis · 2019-07-17 · $649
  • Travel for Kyprolis · 2019-05-08 · $140
  • Meals for Kyprolis · 2019-05-02 · $152
  • Travel for Kyprolis · 2019-05-02 · $110
  • Travel · 2019-04-08 · $98
  • Travel for Kyprolis · 2019-04-05 · $184
  • Consulting for Kyprolis · 2019-04-01 · $3,300
  • Travel for Kyprolis · 2019-03-23 · $79
  • Meals for Kyprolis · 2019-03-22 · $81
  • Travel for Kyprolis · 2019-03-22 · $158
  • Travel for Kyprolis · 2019-03-21 · $466
  • Travel for Kyprolis · 2019-03-21 · $6,663
  • Consulting · 2019-03-15 · $4,400
  • Consulting · 2019-03-15 · $1,650
  • Meals for Kyprolis · 2019-03-09 · $150
  • Travel for Kyprolis · 2019-03-08 · $156
  • Travel for Kyprolis · 2019-03-08 · $353
  • Travel for Kyprolis · 2019-03-08 · $363
  • Meals for Kyprolis · 2019-01-10 · $65
  • Travel for Kyprolis · 2019-01-10 · $810
CelgeneRevlimid$17,561
13 payments
  • Travel · 2019-12-13 · $99
  • Meals · 2019-11-01 · $49
  • Meals for Revlimid · 2019-07-26 · $22
  • Travel for Revlimid · 2019-07-26 · $1,123
  • Consulting for Jcar017 · 2019-07-11 · $2,000
  • Travel for Revlimid · 2019-05-31 · $1,984
  • Paid to speak or teach for Revlimid · 2019-05-31 · $544
  • Paid to speak or teach for Revlimid · 2019-05-31 · $3,150
  • Paid to speak or teach for Revlimid · 2019-05-08 · $1,155
  • Travel for Revlimid · 2019-05-08 · $1,984
  • Paid to speak or teach for Revlimid · 2019-05-08 · $3,150
  • Consulting for Jcar017 · 2019-02-21 · $2,000
  • Travel for Revlimid · 2019-01-03 · $300
GenzymeCd38$12,155
18 payments
  • Travel for Cd38 · 2019-06-26 · $265
  • Travel for Cd38 · 2019-06-26 · $385
  • Meals for Cd38 · 2019-06-26 · $37
  • Meals for Cd38 · 2019-06-26 · $51
  • Consulting for Cd38 · 2019-06-26 · $3,495
  • Meals for Cd38 · 2019-06-26 · $41
  • Travel for Cd38 · 2019-06-26 · $125
  • Travel for Cd38 · 2019-06-26 · $30
  • Meals for Cd38 · 2019-06-26 · $70
  • Travel for Cd38 · 2019-05-17 · $327
  • Travel for Cd38 · 2019-05-17 · $342
  • Travel for Cd38 · 2019-05-17 · $258
  • Meals for Cd38 · 2019-05-17 · $43
  • Meals for Cd38 · 2019-05-17 · $14
  • Meals for Cd38 · 2019-05-17 · $59
  • Meals for Cd38 · 2019-05-17 · $14
  • Consulting for Cd38 · 2019-05-17 · $6,500
  • Travel for Cd38 · 2019-05-17 · $100
E.R. Squibb & Sons L.L.C.Empliciti$3,990
2 payments
  • Consulting for Empliciti · 2019-12-16 · $2,280
  • Consulting for Empliciti · 2019-02-13 · $1,710
Janssen Scientific AffairsDarzalex$2,903
2 payments
  • Meals for Darzalex · 2019-10-29 · $125
  • Consulting for Darzalex · 2019-06-11 · $2,778
Janssen Global ServicesDarzalex$2,876
6 payments
  • Consulting for Darzalex · 2019-10-16 · $2,722
  • Meals for Darzalex · 2019-10-16 · $62
  • Meals for Darzalex · 2019-10-16 · $17
  • Meals for Darzalex · 2019-10-16 · $29
  • Meals for Darzalex · 2019-10-16 · $17
  • Meals for Darzalex · 2019-10-16 · $29
Secura BioFarydak$1,602
2 payments
  • Honoraria for Farydak · 2019-12-05 · $1,500
  • Meals for Farydak · 2019-09-15 · $102
Seattle GeneticsNone$1,248
4 payments
  • Paid to speak or teach · 2019-12-07 · $1,150
  • Meals · 2019-12-07 · $21
  • Meals · 2019-12-07 · $29
  • Meals · 2019-12-07 · $47

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64407564 A Humanized Gprc5d X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2021Their institution$3,013,545
Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64407564, A Humanized Gprc5d X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2020Their institution$2,954,915
Janssen Research & Development, LLC · A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma · 2022Their institution$2,899,867
Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64407564, A Humanized Gprc5d X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2019Their institution$2,816,511
Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64407564 A Humanized Gprc5d X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2022Their institution$2,182,633
Janssen Research & Development, LLC · A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma · 2021Their institution$1,726,094
Amgen Inc. · A Phase I Study of the Combination of A Selective Inhibitor of Nuclear Export (Sine), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma. · 2019Their institution$928,560
Amgen Inc. · A Multi-Arm Phase Ib Study of Sar650984 (Isatuximab, An Anti-Cd38 Mab) in Combination With Carfilzomib, High-Dose Carfilzomib and Dexamethasone, and Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed Or Refractory Multiple Myel · 2019Their institution$631,421
Janssen Research & Development, LLC · A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma · 2023Their institution$405,000
Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2021Their institution$333,379
Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64007957, A Humanized Bcma X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2020Their institution$321,109
Celgene Corporation · Phase 1 in Rrmm - A Phase 1, Multi-Center, Open-Label, Dose Finding Study of Cc-92328 (Df3001), A Bcma Targeting Tri-Specific Natural Killer Cell Engager Therapy (Trinket), in Subjects With Relapsed and/Or Refractory Multiple Myeloma. · 2023Their institution$290,202
Janssen Research & Development, LLC · An Open-Label, Multicenter, Dose Escalation Phase 1b Study To Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (Rhuph20) for the Treatment of Subjects With Relapsed Or Refractory Multiple Myeloma · 2019Their institution$268,079
Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64407564 A Humanized Gprc5d X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2023Their institution$261,121
GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2019Their institution$249,342
Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2022Their institution$236,843
Janssen Research & Development, LLC · A Multi Arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 2022Their institution$191,094
Janssen Research & Development, LLC · A Multicenter Phase 2 Study To Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens · 2019Their institution$179,444
Janssen Research & Development, LLC · Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-Rvd) Versus Lenalidomide, Bortezomib, and Dexamethasone (Rvd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation · 2019Their institution$150,292
Janssen Research & Development, LLC · A Phase 2 Study of Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients · 2020Their institution$146,553
Celgene Corporation · Study To Evaluate the Safety and Tolerability of Cc-92328 in Participants With Relapsed and/Or Refractory Multiple Myeloma · 2024Their institution$139,461
Janssen Research & Development, LLC · A Multi Arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 2023Their institution$135,521
Celgene Corporation · Phase 1 in Rrmm - A Phase 1, Multi-Center, Open-Label, Dose Finding Study of Cc-92328 (Df3001), A Bcma Targeting Tri-Specific Natural Killer Cell Engager Therapy (Trinket), in Subjects With Relapsed and/Or Refractory Multiple Myeloma. · 2022Their institution$128,564
Janssen Research & Development, LLC · Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-Rvd) Versus Lenalidomide, Bortezomib, and Dexamethasone (Rvd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation · 2020Their institution$108,057
Janssen Research & Development, LLC · A Phase 2 Study of Daratumumab in Combination With Dose Attenuated Bortezomib Lenalidomide and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients · 2021Their institution$84,641
Janssen Research & Development, LLC · An Open-Label, Multicenter, Dose Escalation Phase 1b Study To Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (Rhuph20) for the Treatment of Subjects With Relapsed Or Refractory Multiple Myeloma · 2020Their institution$81,086
Janssen Research & Development, LLC · Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone Drvd Versus Lenalidomide Bortezomib and Dexamethasone Rvd in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High Dose Chemotherapy and Autologo · 2021Their institution$76,585
Janssen Research & Development, LLC · A Multicenter Phase 2 Study To Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens · 2020Their institution$69,421
Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2022Their institution$68,583
Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2023Their institution$66,222
Pharmacyclics LLC, an AbbVie Company · A Multicenter Phase 1/2b Study of the Brutons Tyrosine Kinase Inhibitor, Ibrutinib (Pci-32765), in Combination With Carfilzomib (Kyprolis) in Subjects With Relapsed Or Relapsed and Refractory Multiple Myeloma · 2021Their institution$59,861
Celgene Corporation · A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophospamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma · 2020Their institution$52,358
Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2019Their institution$47,172
Seattle Genetics, Inc. · Phase 1 Study of Sgn-Cd48a in Patients With Relapsed Or Refractory Multiple Myeloma · 2019Their institution$39,989
GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2023Their institution$39,874
Amgen Inc. · A Phase I Study of the Combination of A Selective Inhibitor of Nuclear Export (Sine), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma. · 2021Their institution$38,966
Janssen Research & Development, LLC · Protocol - 54757414-Mmy-1001: An Open-Label, Multicenter, Phase 1b Study of Jnj-54767414 (Humax Cd38) (Anti-Cd38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma · 2019Their institution$34,578
Janssen Research & Development, LLC · Phase 1, First-in-Human, Dose Escalation Study of Jnj-79635322, A Trispecific Antibody, in Participants With Relapsed Or Refractory Multiple Myeloma · 2024Their institution$34,338
Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2021Their institution$32,453
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I/II Study of the Addition of Ixazomib To Onc201 and Dexamethasone in Relapsed and/Or Refractory Multiple Myeloma · 2020Their institution$31,057
Janssen Research & Development, LLC · Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (Drd) Vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Or Refractory Multiple Myeloma · 2019Their institution$28,015
Takeda Pharmaceuticals U.S.A., Inc. · The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma Insight · 2019Their institution$26,876
Janssen Research & Development, LLC · A Multi Center Phase 2 Study To Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens · 2021Their institution$25,649
Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2022Their institution$25,444
Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64007957, A Humanized Bcma X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2019Their institution$22,590
Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2020Their institution$21,987
Array BioPharma Inc. · An Open-Label, Multicenter Rollover Study To Allow Continued Access To Filanesib (Arry-520) for Patients With Multiple Myeloma Who Are Currently Receiving Filanesib in Studies Sponsored By Array Biopharma Inc. · 2019Their institution$21,078
Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2021Their institution$20,264
GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2020Their institution$18,968
GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2021Their institution$18,688
Janssen Research & Development, LLC · A Phase 3 Study Comparing Daratumumab . Lenalidomide and Dexamethasone (Drd) Versus Lenalidomide and Dexamethasone (Rd) in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplant · 2019Their institution$18,339
Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2020Their institution$16,606
Takeda Pharmaceuticals U.S.A., Inc. · An Open-Label, Dose-Escalation, Phase 1-2 Study of the Oral Formulation of Mln9708 Administered Twice-Weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment · 2019This clinician$14,887
ARRAY BIOPHARMA INC · An Openlabel Multicenter Rollover Study To Allow Continued Access To Filanesib Array520 for Patients With Mulitple Myeloma Who Are Currently Receiving Filanesib in Studies Sponsored By Array Biopharma Inc · 2020Their institution$14,563
Janssen Research & Development, LLC · A Phase 3 Study Comparing Daratumumab . Lenalidomide and Dexamethasone (Drd) Versus Lenalidomide and Dexamethasone (Rd) in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplant · 2020Their institution$14,058
GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2022Their institution$11,820
Janssen Research & Development, LLC · Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone Drvd Versus Lenalidomide Bortezomib and Dexamethasone Rvd in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplantation · 2022Their institution$9,445
Janssen Research & Development, LLC · A Phase 2 Study of Daratumumab in Combination With Dose Attenuated Bortezomib Lenalidomide and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients · 2022Their institution$9,443
Janssen Research & Development, LLC · Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (Drd) Vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Or Refractory Multiple Myeloma · 2020Their institution$8,250
Amgen Inc. · A Combination of Carfilzomib, Dexamethasone, and Daratumumab for Treatment of Adult Patients With Relapsed/Refractory Multiple Myeloma in Two Dosing Regimens: Once-Weekly and Twice-Weekly · 2021This clinician$7,626
Janssen Research & Development, LLC · A Phase 3 Study Comparing Daratumumab . Lenalidomide and Dexamethasone Drd Versus Lenalidomide and Dexamethasone Rd in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplant · 2021Their institution$6,325
Janssen Research & Development, LLC · An Open Label Multi Center Dose Escalation Phase 1b Study To Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase Rhuph20 for the Treatment of Subjects With Relapsed Or Refracto · 2021Their institution$5,866
Takeda Pharmaceuticals U.S.A., Inc. · The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma Insight · 2019This clinician$5,211
Amgen Inc. · B-Cell Maturation Antigen (Bcma) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches · 2020This clinician$4,146
Janssen Research & Development, LLC · Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone Drd Vs Lenalidomide and Dexamethasone Rd in Subjects With Relapsed Or Refractory Multiple Myeloma · 2022Their institution$3,600
Taiho Oncology, Inc. · 2019Their institution$3,250
Seagen Inc. · Phase 1 Study of Sgn-Cd48a in Patients With Relapsed Or Refractory Multiple Myeloma · 2020Their institution$3,175
Janssen Research & Development, LLC · Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone Drd Vs Lenalidomide and Dexamethasone Rd in Subjects With Relapsed Or Refractory Multiple Myeloma · 2021Their institution$3,050
Celgene Corporation · A Phase 1, Multi-Center, Open-Label, Dose Finding Study of Cc-92328 (Df3001), A Bcma Targeting Tri-Specific Natural Killer Cell Engager Therapy (Trinket), in Subjects With Relapsed and/Or Refractory Multiple Myeloma. · 2025Their institution$3,034
Janssen Research & Development, LLC · A Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 2022Their institution$3,000
Janssen Research & Development, LLC · Protocol - 54757414-Mmy-1001: An Open-Label, Multicenter, Phase 1b Study of Jnj-54767414 (Humax Cd38) (Anti-Cd38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma · 2020Their institution$2,756
Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2023Their institution$2,596
Amgen Inc. · Comparison of Efficacy Outcomes for Carfilzomib Plus Dexamethasone and Daratumumab (Kdd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (Pvd) and D-Pd in Relapsed Or Refractory Multiple Myeloma · 2021This clinician$1,349
Janssen Research & Development, LLC · A Phase 3 Study Comparing Daratumumab . Lenalidomide and Dexamethasone Drd Versus Lenalidomide and Dexamethasone Rd in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplant · 2022Their institution$503
Amgen Inc. · Efficacy and Safety of Weekly Carfilzomib (70 Mg/M 2), Dexamethasone, and Daratumumab (Kdd70) Is Co · 2020This clinician$463
Amgen Inc. · Efficacy and Safety of Carfilzomib, Dexamethasone, and Daratumumab (Kdd) Twice-Weekly at 56 Mg/M2 An · 2020This clinician$175
Amgen Inc. · P3 Kd V Kdd in Relapsed/Refractory Mm (Candor) · 2020This clinician$12

Professional record

NPI
1376560136
Licence
NY 219311
Trained
University of California, Geffen School of Medicine, 1999 · 27 years ago
Group
UCSF Medical Group Business Services · University of California San Francisco · Regents of the University of California
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
400 Parnassus Ave, San Francisco, CA, 94143
NPI first listed
2006-07-17
NPI last updated
2024-01-21
NPI record certified
2024-01-21

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 400 Parnassus Ave, San Francisco, CA, 94143